Kavar Capital Partners Group Portfolio holdings
Top Buys
| 1 |
Vanguard Value ETF
VTV
|
+$1.63M |
| 2 |
Edwards Lifesciences
EW
|
+$1.32M |
| 3 |
Microsoft
MSFT
|
+$1.15M |
| 4 |
Schwab US TIPS ETF
SCHP
|
+$881K |
| 5 |
Thermo Fisher Scientific
TMO
|
+$849K |
Top Sells
| 1 |
BSX.PRA
Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A
BSX.PRA
|
+$459K |
| 2 |
EPR Properties
EPR
|
+$403K |
| 3 |
Griffon
GFF
|
+$258K |
| 4 |
SPLK
Splunk Inc
SPLK
|
+$207K |
| 5 |
S&P Global
SPGI
|
+$206K |
Sector Composition
| 1 | Healthcare | 17.86% |
| 2 | Technology | 13.26% |
| 3 | Consumer Staples | 11.19% |
| 4 | Financials | 10.19% |
| 5 | Communication Services | 7% |
Similar funds
Kavar Capital Partners Group's Q4 2020 Portfolio in Review
As of Q4 2020, Kavar Capital Partners Group held 156 positions worth $348M, up 17% from $297M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Kavar Capital Partners Group deployed $11.6M of net new capital in Q4 2020, opening 12 new positions and adding to 53 existing holdings. Its largest new stake was Vanguard Value ETF: 14,484 shares worth $1.72M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, down from 19% a quarter earlier, followed by Technology and Consumer Staples.
On the sell side, the largest reduction was Griffon, an estimated $258K trimmed.
- Kavar Capital Partners Group's largest Q4 2020 buy was Vanguard Value ETF: 14,484 shares worth $1.72M.
- Kavar Capital Partners Group added most to Edwards Lifesciences in Q4 2020, an estimated $1.32M increase.
- Kavar Capital Partners Group's biggest Q4 2020 reduction was Griffon, cutting an estimated $258K.
- Kavar Capital Partners Group fully exited Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A in Q4 2020, selling an estimated $459K.
- Kavar Capital Partners Group's ten largest holdings make up 33% of its $348M portfolio in Q4 2020.
- Kavar Capital Partners Group opened 12 new positions and closed 4 in Q4 2020.
- Kavar Capital Partners Group's portfolio value rose 17% quarter-over-quarter to $348M.
Based on Kavar Capital Partners Group's 13F filing for Q4 2020, filed 5 Feb 2021.